98%
921
2 minutes
20
We previously reported an ability of low-intensity vibration (LIV) to improve selected biomarkers of bone turnover and gene expression and reduce osteoclastogenesis but lacking of evident bone accrual. In this study, we demonstrate that a prolonged course of LIV that initiated at 2 weeks post-injury and continued for 8 weeks can protect against bone loss after SCI in rats. LIV stimulates bone formation and improves osteoblast differentiation potential of bone marrow stromal stem cells while inhibiting osteoclast differentiation potential of marrow hematopoietic progenitors to reduce bone resorption. We further demonstrate that the combination of LIV and RANKL antibody reduces SCI-related bone loss more than each intervention alone. Our findings that LIV is efficacious in maintaining sublesional bone mass suggests that such physical-based intervention approach would be a noninvasive, simple, inexpensive and practical intervention to treat bone loss after SCI. Because the combined administration of LIV and RANKL inhibition better preserved sublesional bone after SCI than either intervention alone, this work provides the impetus for the development of future clinical protocols based on the potential greater therapeutic efficacy of combining non-pharmacological (e.g., LIV) and pharmacological (e.g., RANKL inhibitor or other agents) approaches to treat osteoporosis after SCI or other conditions associated with severe immobilization.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11489065 | PMC |
http://dx.doi.org/10.1016/j.bonr.2024.101808 | DOI Listing |
Calcif Tissue Int
September 2025
FirmoLab, Fondazione F.I.R.M.O. Onlus and Stabilimento Chimico Farmaceutico Militare (SCFM), 50141, Florence, Italy.
X-linked hypophosphatemia (XLH) is a rare and progressive disease, due to inactivating mutations in the phosphate-regulating endopeptidase homolog X-linked (PHEX) gene. These pathogenic variants result in elevated circulating levels of fibroblast growth factor 23 (FGF23), responsible for the main clinical manifestations of XLH, such as hypophosphatemia, skeletal deformities, and mineralization defects. However, XLH also involves muscular disorders (muscle weakness, pain, reduced muscle density, peak strength, and power).
View Article and Find Full Text PDFActa Ortop Mex
September 2025
Servicio de Ortopedia y Traumatología, Hospital de San Rafael, Hospitales Pascual. Cádiz, España.
Introduction: anatomical deformities such as developmental dysplasia of the hip (DDH) and Perthes disease represent a challenge for reconstruction. The use of 3D-printed models can be helpful for assessing the deformity, bone mass, implant size, and orientation.
Objectives: to prospectively evaluate the outcomes of 3D simulation in primary total hip arthroplasty.
J Neurol Surg A Cent Eur Neurosurg
September 2025
Neurosurgery, University of Tsukuba Institute of Medicine, Tsukuba, Japan.
Background: Intracranial solitary fibrous tumors (SFTs) are rare mesenchymal tumors often presenting with dural-based lesions. These tumors can exhibit aggressive characteristics with high recurrence rates and extracranial metastasis. While SFTs occasionally invade venous sinuses, cases where the tumor arises within the venous sinus are rare.
View Article and Find Full Text PDFSci Total Environ
September 2025
Department of Orthopedics and Traumatology, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, Sichuan Province, China. Electronic address:
The objective of this research was to use a network toxicology approach to examine the possible toxicity of the cigarette toxicants nicotine and coal tar that cause osteoporosis (OP) as well as its molecular processes. We determined the primary chemical structures and 128 targets of action of tar and nicotine using the Swiss Target Prediction, NP-MRD, and PubChem databases. We discovered that genes including DNAJB1, CCDC8, LINC00888, ATP6V1G1, MPV17L2, PPCS, and TACC1 had a disease prognostic guiding value by LASSO analysis and differential analysis of GEO microarray data.
View Article and Find Full Text PDFIntroduction: The ADHEAR is a non-surgical Bone Conduction Device (BCD) that makes use of an adhesive adapter. While clinical trials have demonstrated its efficacy with regards to audiological performance, safety and compliance, data on real-world paediatric cohorts is scarce.
Methods: This retrospective cohort study analysed data from paediatric patients fitted with ADHEAR at a tertiary centre between January 2017 and September 2024.